Molecular Accounts Payable vs Property Plant Equipment Analysis

MOLN Stock

USD 5.42 0.22 4.23%

Molecular Partners financial indicator trend analysis is infinitely more than just investigating Molecular Partners recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Molecular Partners is a good investment. Please check the relationship between Molecular Partners Accounts Payable and its Property Plant Equipment accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Accounts Payable vs Property Plant Equipment

Accounts Payable vs Property Plant Equipment Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Molecular Partners Accounts Payable account and Property Plant Equipment. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Molecular Partners' Accounts Payable and Property Plant Equipment is 0.51. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Molecular Partners AG, assuming nothing else is changed. The correlation between historical values of Molecular Partners' Accounts Payable and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Molecular Partners AG are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Accounts Payable i.e., Molecular Partners' Accounts Payable and Property Plant Equipment go up and down completely randomly.

Correlation Coefficient

0.51

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Molecular Partners obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Molecular Partners are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Property Plant Equipment

Most indicators from Molecular Partners' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

As of the 22nd of November 2024, Sales General And Administrative To Revenue is likely to grow to 2.83, while Selling General Administrative is likely to drop about 12.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	548K	605K	49K	46.6K
Depreciation And Amortization	2.6M	2.4M	2.4M	2.0M

Interest Expense Depreciation And Amortization

Molecular Partners fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.69	-0.04	0.96	0.47	-0.16	-0.26	-0.38	0.15	0.33	0.45	-0.34	0.96	-0.28	0.67	0.54	-0.53	-0.47	-0.3	0.74	-0.36	0.58	1.0	-0.7	0.01	0.72
Other Current Liab	0.69		0.21	0.71	0.78	-0.08	0.39	-0.85	0.51	-0.34	0.8	-0.49	0.57	-0.05	0.95	0.89	-0.83	-0.75	-0.12	0.97	-0.42	0.82	0.66	-0.73	0.57	0.98
Total Current Liabilities	-0.04	0.21		-0.24	0.54	0.95	0.01	-0.43	0.8	-0.02	0.55	-0.51	-0.17	0.39	0.27	0.1	0.11	0.05	0.18	0.24	0.75	-0.01	-0.07	-0.16	0.42	0.16
Total Stockholder Equity	0.96	0.71	-0.24		0.39	-0.38	-0.18	-0.35	0.02	0.24	0.37	-0.26	0.95	-0.35	0.69	0.58	-0.63	-0.51	-0.31	0.74	-0.6	0.6	0.96	-0.7	0.0	0.74
Property Plant And Equipment Net	0.47	0.78	0.54	0.39		0.29	0.38	-0.85	0.62	-0.32	1.0	-0.5	0.41	-0.21	0.81	0.79	-0.54	-0.5	-0.38	0.81	0.03	0.75	0.42	-0.42	0.48	0.81
Current Deferred Revenue	-0.16	-0.08	0.95	-0.38	0.29		-0.21	-0.13	0.63	0.18	0.29	-0.44	-0.26	0.4	0.0	-0.2	0.37	0.32	0.24	-0.04	0.86	-0.3	-0.18	0.0	0.23	-0.13
Net Debt	-0.26	0.39	0.01	-0.18	0.38	-0.21		-0.55	0.17	-0.99	0.4	0.03	-0.36	0.23	0.29	0.61	-0.39	-0.65	0.18	0.27	-0.2	0.57	-0.29	0.18	0.48	0.37
Retained Earnings	-0.38	-0.85	-0.43	-0.35	-0.85	-0.13	-0.55		-0.67	0.48	-0.87	0.32	-0.25	-0.02	-0.87	-0.82	0.75	0.69	0.14	-0.87	0.14	-0.82	-0.34	0.58	-0.65	-0.86
Accounts Payable	0.15	0.51	0.8	0.02	0.62	0.63	0.17	-0.67		-0.16	0.64	-0.38	-0.01	0.38	0.51	0.39	-0.2	-0.28	0.09	0.54	0.4	0.28	0.12	-0.47	0.57	0.44
Cash	0.33	-0.34	-0.02	0.24	-0.32	0.18	-0.99	0.48	-0.16		-0.34	-0.03	0.43	-0.28	-0.25	-0.57	0.31	0.59	-0.23	-0.21	0.18	-0.48	0.35	-0.24	-0.46	-0.31
Non Current Assets Total	0.45	0.8	0.55	0.37	1.0	0.29	0.4	-0.87	0.64	-0.34		-0.53	0.38	-0.18	0.82	0.78	-0.55	-0.5	-0.36	0.81	0.03	0.74	0.41	-0.44	0.54	0.82
Non Currrent Assets Other	-0.34	-0.49	-0.51	-0.26	-0.5	-0.44	0.03	0.32	-0.38	-0.03	-0.53		-0.29	0.01	-0.42	-0.26	0.23	-0.02	-0.11	-0.4	-0.15	-0.06	-0.32	0.44	-0.55	-0.37
Cash And Short Term Investments	0.96	0.57	-0.17	0.95	0.41	-0.26	-0.36	-0.25	-0.01	0.43	0.38	-0.29		-0.52	0.59	0.44	-0.47	-0.3	-0.5	0.64	-0.42	0.5	0.96	-0.64	-0.1	0.63
Net Receivables	-0.28	-0.05	0.39	-0.35	-0.21	0.4	0.23	-0.02	0.38	-0.28	-0.18	0.01	-0.52		-0.14	-0.07	0.2	-0.24	0.9	-0.12	0.39	-0.18	-0.28	0.11	0.17	-0.16
Common Stock Total Equity	0.67	0.95	0.27	0.69	0.81	0.0	0.29	-0.87	0.51	-0.25	0.82	-0.42	0.59	-0.14		0.86	-0.79	-0.65	-0.23	0.98	-0.36	0.79	0.64	-0.73	0.47	0.98
Common Stock Shares Outstanding	0.54	0.89	0.1	0.58	0.79	-0.2	0.61	-0.82	0.39	-0.57	0.78	-0.26	0.44	-0.07	0.86		-0.71	-0.86	-0.17	0.87	-0.4	0.92	0.51	-0.41	0.38	0.93
Non Current Liabilities Total	-0.53	-0.83	0.11	-0.63	-0.54	0.37	-0.39	0.75	-0.2	0.31	-0.55	0.23	-0.47	0.2	-0.79	-0.71		0.67	0.17	-0.82	0.69	-0.77	-0.51	0.68	-0.44	-0.83
Inventory	-0.47	-0.75	0.05	-0.51	-0.5	0.32	-0.65	0.69	-0.28	0.59	-0.5	-0.02	-0.3	-0.24	-0.65	-0.86	0.67		-0.13	-0.71	0.42	-0.88	-0.45	0.31	-0.27	-0.76
Other Current Assets	-0.3	-0.12	0.18	-0.31	-0.38	0.24	0.18	0.14	0.09	-0.23	-0.36	-0.11	-0.5	0.9	-0.23	-0.17	0.17	-0.13		-0.23	0.22	-0.3	-0.28	0.14	0.12	-0.24
Other Stockholder Equity	0.74	0.97	0.24	0.74	0.81	-0.04	0.27	-0.87	0.54	-0.21	0.81	-0.4	0.64	-0.12	0.98	0.87	-0.82	-0.71	-0.23		-0.38	0.83	0.71	-0.77	0.46	0.99
Total Liab	-0.36	-0.42	0.75	-0.6	0.03	0.86	-0.2	0.14	0.4	0.18	0.03	-0.15	-0.42	0.39	-0.36	-0.4	0.69	0.42	0.22	-0.38		-0.43	-0.37	0.34	0.02	-0.44
Property Plant And Equipment Gross	0.58	0.82	-0.01	0.6	0.75	-0.3	0.57	-0.82	0.28	-0.48	0.74	-0.06	0.5	-0.18	0.79	0.92	-0.77	-0.88	-0.3	0.83	-0.43		0.55	-0.41	0.31	0.88
Total Current Assets	1.0	0.66	-0.07	0.96	0.42	-0.18	-0.29	-0.34	0.12	0.35	0.41	-0.32	0.96	-0.28	0.64	0.51	-0.51	-0.45	-0.28	0.71	-0.37	0.55		-0.69	-0.02	0.69
Short Term Debt	-0.7	-0.73	-0.16	-0.7	-0.42	0.0	0.18	0.58	-0.47	-0.24	-0.44	0.44	-0.64	0.11	-0.73	-0.41	0.68	0.31	0.14	-0.77	0.34	-0.41	-0.69		-0.47	-0.68
Intangible Assets	0.01	0.57	0.42	0.0	0.48	0.23	0.48	-0.65	0.57	-0.46	0.54	-0.55	-0.1	0.17	0.47	0.38	-0.44	-0.27	0.12	0.46	0.02	0.31	-0.02	-0.47		0.44
Common Stock	0.72	0.98	0.16	0.74	0.81	-0.13	0.37	-0.86	0.44	-0.31	0.82	-0.37	0.63	-0.16	0.98	0.93	-0.83	-0.76	-0.24	0.99	-0.44	0.88	0.69	-0.68	0.44

Click cells to compare fundamentals

Molecular Partners Account Relationship Matchups

Molecular Partners fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	104.9M	187.5M	172.7M	262.3M	198.4M	193.3M
Other Current Liab	7.0M	9.4M	11.6M	15.1M	12.8M	7.8M
Total Current Liabilities	28.6M	57.7M	46.9M	17.3M	14.4M	13.7M
Total Stockholder Equity	54.1M	107.2M	107.3M	235.2M	176.4M	137.3M
Property Plant And Equipment Net	4.2M	9.4M	8.1M	7.2M	5.7M	4.7M
Current Deferred Revenue	18.3M	42.9M	28.3M	6.4M	4.3M	4.1M
Net Debt	(73.2M)	(126.5M)	(65.8M)	(83.1M)	(63.7M)	(66.8M)
Retained Earnings	(130.9M)	(195.2M)	(251.0M)	(127.8M)	(191.8M)	(182.2M)
Accounts Payable	2.0M	2.8M	4.9M	997K	410K	389.5K
Cash	75.7M	133.7M	71.8M	87.9M	67.3M	94.3M
Non Current Assets Total	5.0M	9.7M	8.5M	7.5M	5.9M	5.0M
Cash And Short Term Investments	95.1M	173.7M	132.8M	249.1M	186.9M	175.8M
Net Receivables	2.5M	159K	25.7M	521K	295K	280.3K
Common Stock Total Equity	2.1M	2.1M	2.2M	2.9M	3.4M	2.3M
Common Stock Shares Outstanding	21.4M	25.0M	31.0M	33.3M	32.8M	26.0M
Liabilities And Stockholders Equity	104.9M	187.5M	172.7M	262.3M	198.4M	193.3M
Non Current Liabilities Total	22.2M	22.7M	18.5M	9.8M	7.5M	7.1M
Inventory	(51.6M)	(486K)	(199K)	(86.7M)	(78.1M)	(74.2M)
Other Current Assets	2.8M	1.3M	5.7M	3.9M	2.5M	2.4M
Other Stockholder Equity	182.8M	299.5M	355.0M	359.3M	364.5M	250.8M
Total Liab	50.8M	80.3M	65.4M	27.1M	21.9M	40.7M
Property Plant And Equipment Gross	4.2M	9.4M	20.9M	21.9M	22.0M	23.1M
Total Current Assets	99.9M	177.8M	164.2M	254.8M	192.5M	188.3M
Intangible Assets	772K	347K	330K	271K	212K	245.5K
Common Stock	2.2M	2.9M	3.2M	3.6M	3.6M	2.7M
Short Term Investments	19.4M	40M	61M	161.2M	119.6M	125.6M
Other Liab	20.9M	16.6M	13.7M	6.2M	5.6M	5.3M
Net Tangible Assets	53.4M	106.9M	107.0M	234.9M	270.1M	283.6M
Net Invested Capital	54.1M	107.2M	107.3M	235.2M	176.4M	139.6M
Net Working Capital	71.3M	120.1M	117.3M	237.5M	178.0M	152.3M
Property Plant Equipment	4.2M	9.4M	8.1M	7.2M	8.3M	5.9M
Capital Stock	2.2M	2.9M	3.2M	3.6M	3.6M	3.2M

Pair Trading with Molecular Partners

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.

Moving against Molecular Stock

0.39

Agilent Technologies Earnings Call This Week

Pair Corr

The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.

The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:

How To Invest In Molecular

Details

Is Molecular Stock a good investment?

Details

What is Molecular Partners' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.14)

Revenue Per Share

0.182

Quarterly Revenue Growth

(0.73)

Return On Assets

(0.21)

Return On Equity

(0.37)

The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Molecular Accounts Payable vs Property Plant Equipment Analysis

Accounts Payable vs Property Plant Equipment

Accounts Payable vs Property Plant Equipment Correlation Analysis

Correlation Coefficient

Accounts Payable

Property Plant Equipment

Molecular Partners fundamental ratios Correlations

Molecular Partners Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Molecular Partners fundamental ratios Accounts

Pair Trading with Molecular Partners

Moving against Molecular Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 0.99	Other Stockholder Equity
Common Stock	+ 0.98	Other Current Liab
Other Stockholder Equity	+ 0.98	Common Stock Total Equity
Common Stock	+ 0.98	Common Stock Total Equity

Cash	- 0.99	Net Debt
Property Plant And Equipment Gross	- 0.88	Inventory
Other Stockholder Equity	- 0.87	Retained Earnings
Common Stock Total Equity	- 0.87	Retained Earnings
Non Current Assets Total	- 0.87	Retained Earnings
Inventory	- 0.86	Common Stock Shares Outstanding